Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome

Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products AHMEDABAD, India and SOLANA ...

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

The Progeria Research Foundation ("PRF"), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome ("Progeria"), and Forge Biologics, ...
The Cincinnati Enquirer

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria – an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1’s effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir ...
Florida Today

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria – an Ultra-Rare Genetic Disorder that Causes Rapid Aging

MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases ...